Cytoxan

(cyclophosphamide)

ApprovedSmall molecule

Cyclophosphamide is a chemotherapy drug used to treat various cancers including lymphomas and leukemias, and is also used to treat certain autoimmune diseases like lupus and rheumatoid arthritis by suppressing the immune system.[2] Cytoxan is currently approved and in use across 332 indications[4].[1]

Cytoxan is one of 3125 small molecule programs targeting Glioma. It is currently in Approved.

332

Indications

3,008

Total Trials

Active Trials

3,124

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Childhood CancerActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Childhood Acute Lymphoblastic LeukemiaApproved

EpendymomaActive, not recruiting

FibrosarcomaActive, not recruiting

HIV InfectionActive, not recruiting

Systemic Lupus ErythematosusActive, not recruiting

GranulomaActive, not recruiting

ChordomaActive, not recruiting

GliomaPhase 1

Active, not recruiting

Childhood CancerPhase 2

Active, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 2

Active, not recruiting

Childhood Acute Lymphoblastic LeukemiaApproved

Approved

EpendymomaPhase 3

Active, not recruiting

FibrosarcomaPhase 2

Active, not recruiting

HIV InfectionPhase 1

Active, not recruiting

Systemic Lupus ErythematosusPhase 3

Active, not recruiting

GranulomaPhase 2

Active, not recruiting

ChordomaPhase 1/Phase 2

Active, not recruiting

Showing 10 of 331 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Tecentriq

36 3

Prolia

Amgen

Preclinical

14 4

MS Contin

Merck & Co.

Preclinical

2 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Chantix

PPrism Pharmaceuticals

Preclinical

1 7

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 8

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 9

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 10

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Intraperitoneal

NCT02498912

Phase 1/2Active, not recruiting

Decitabine-Primed Tandem CD19/CD20 CAR T Cells

NCT04697940

Phase 1Active, not recruiting

Lymphoma

NCT02337985

Phase 2Recruiting

Richter's Transformation

NCT05672173

Q4 2026

Phase 2Recruiting

Neuroblastoma

NCT02605421

Phase 2Active, not recruiting

Lymphoma

NCT03749018

Clinical

Trials by Indication[1]

Breast Cancer25 trials

Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women

Completed·UUNICANCER·Phase 2·NCT02400567·125 enrolled

Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00629499·63 enrolled

Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer

Unknown status·HHeinrich-Heine University, Duesseldorf·N/A·NCT00309920·1,234 enrolled

Show 22 more trials

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Completed·UUniversity of Washington·Phase 1/2·NCT00331552·30 enrolled

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05177796

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT05929768·2,400 enrolled

A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT00559845·56 enrolled

MEtronomic TrEatment Option in Advanced bReast cAncer

Completed·EETOP IBCSG Partners Foundation·Phase 2·NCT02954055·140 enrolled

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Completed·SSpanish Breast Cancer Research Group·Phase 3·NCT00129935·1,384 enrolled

Vaccination of High Risk Breast Cancer Patients

Completed·UUniversity of Arkansas·Phase 1/2·NCT02229084·58 enrolled

Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer

Unknown status·YYonsei University·Phase 2·NCT00994968·49 enrolled

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01036087·47 enrolled

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00036868·90 enrolled

SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)

Completed· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 3·NCT02643420·406 enrolled

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT02605915·98 enrolled

A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer

Completed· Amgen logo

Amgen·Phase 2·NCT00124111

Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT00008034·15 enrolled

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer

Completed·—·Phase 1·NCT00496665·25 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Withdrawn·—·Phase 1/2·NCT00006123

Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients

Unknown status·ZZhejiang University·Phase 4·NCT03123770·384 enrolled

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Completed·—·Phase 2·NCT01847001·10 enrolled

Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT00028964

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Completed·—·Phase 2·NCT02978495·154 enrolled

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting·BBriaCell Therapeutics Corporation·Phase 3·NCT06072612·404 enrolled

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

Terminated·UUniversity of Southern California·Phase 2·NCT01873833·10 enrolled

Lymphoma24 trials

Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T

Recruiting·BBGI, China·Phase 1·NCT06224049·6 enrolled

Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

Recruiting·GGALIA AVRAHAMI·N/A·NCT02797717·2,200 enrolled

Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Unknown status·SSun Yat-sen University·Phase 2·NCT03321890·102 enrolled

Show 21 more trials

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Unknown status·—·Phase 1/2·NCT05776407·12 enrolled

Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients

Completed·—·Phase 1/2·NCT00562978·54 enrolled

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting·—·Phase 2·NCT03749018·30 enrolled

Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Unknown status· Amgen logo

Amgen·Phase 2·NCT00005959

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445535·15 enrolled

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00822120·371 enrolled

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03049449·26 enrolled

Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Unknown status·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 3·NCT00028717·400 enrolled

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00005089·71 enrolled

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

Active, not recruiting·—·Phase 1·NCT02337985·10 enrolled

Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Completed·CCancer Research Campaign Clinical Trials Centre·Phase 3·NCT00002576·200 enrolled

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Completed· Roche logo

Roche·Phase 1/2·NCT02055820·267 enrolled

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

Completed· Gilead logo

Gilead·Phase 2·NCT05459571·35 enrolled

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

Completed· Gilead logo

Gilead·Phase 2·NCT04002401·27 enrolled

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Active, not recruiting·BBenjamin Tomlinson·Phase 1·NCT03434769·31 enrolled

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 2·NCT00002941·69 enrolled

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00562965·29 enrolled

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Completed· Gilead logo

Gilead·Phase 3·NCT03391466·359 enrolled

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00302003·287 enrolled

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT01336933·34 enrolled

Multiple Myeloma14 trials

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma

Completed·MMayo Clinic·Phase 1/2·NCT00450814·48 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003401

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT01055301

Show 11 more trials

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·Phase 1·NCT04626752·50 enrolled

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Terminated·AAllogene Therapeutics·Phase 1/2·NCT05000450·6 enrolled

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00040937·147 enrolled

Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00813150·96 enrolled

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Completed·MMedical College of Wisconsin·Phase 2·NCT05032820·40 enrolled

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06045806·79 enrolled

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·—·Phase 2·NCT00941720·71 enrolled

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03602612·35 enrolled

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Terminated·UUniversity of Washington·Phase 1/2·NCT00849251·31 enrolled

Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT00609167·63 enrolled

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06140966·54 enrolled

Acute Lymphoblastic Leukemia11 trials

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT01190930·9,350 enrolled

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

Completed·MMehrdad Abedi, MD·Phase 1·NCT02293109·10 enrolled

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT05032183·4 enrolled

Show 8 more trials

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00671034·166 enrolled

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Withdrawn·UUniversity of Washington·Phase 2·NCT02538926

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Completed·PPETHEMA Foundation·Phase 4·NCT00526305·100 enrolled

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·Phase 1·NCT04626765·50 enrolled

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT01117441·6,136 enrolled

German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·GGoethe University·Phase 4·NCT00198978·377 enrolled

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01319981·31 enrolled

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

Completed·CChildren's Oncology Group·Phase 1·NCT00866307·104 enrolled

Chronic Lymphocytic Leukemia8 trials

Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003764·280 enrolled

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Active, not recruiting·AAllogene Therapeutics·Phase 1/2·NCT04416984·160 enrolled

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00625729·6 enrolled

Show 5 more trials

Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00006390

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00049413

CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01653717·30 enrolled

Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01076556·9 enrolled

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00546377·50 enrolled

82 more indications

Leukemia7 trials

Monoclonal Antibody Therapy, Cyclophosphamide, and Total-Body Irradiation Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Recurrent Acute Lymphocytic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003870·40 enrolled

Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00665990·49 enrolled

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT04029038

Show 4 more trials

Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma

Unknown status·TThe Second Affiliated Hospital of Henan University of Traditional Chinese Medicine·Phase 1/2·NCT02685670·20 enrolled

CD34+ Transplants for Leukemia and Lymphoma

Not yet recruiting·GGuenther Koehne·Phase 2·NCT05565105·100 enrolled

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 2·NCT00939653·6 enrolled

Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation

Completed·—·Phase 1·NCT00057005·6 enrolled

Diffuse Large B-Cell Lymphoma6 trials

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00301821·107 enrolled

Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Completed·SSamsung Medical Center·Phase 2·NCT02670616·24 enrolled

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Recruiting·LLi Zhiming·Phase 2·NCT05422066·50 enrolled

Show 3 more trials

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03003520·46 enrolled

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Terminated· Roche logo

Roche·Phase 3·NCT01287741·1,418 enrolled

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07164469·100 enrolled

Neuroblastoma6 trials

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00033293·53 enrolled

A Study of N9 Chemotherapy in Children With Neuroblastoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04947501·26 enrolled

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma

Unknown status·CChildren's Cancer and Leukaemia Group·N/A·NCT00287950·120 enrolled

Show 3 more trials

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02605421·12 enrolled

Combination Chemotherapy in Treating Children With Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00003093·573 enrolled

Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01857934·153 enrolled

Advanced Solid Tumors6 trials

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

Recruiting·—·Phase 1/2·NCT05681650·30 enrolled

NeoTIL in Advanced Solid Tumors

Active, not recruiting·—·Phase 1·NCT04643574·42 enrolled

Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors

Not yet recruiting·PPeking University·Phase 1·NCT06825455·18 enrolled

Show 3 more trials

ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors

Completed·XXinqiao Hospital of Chongqing·Phase 1/2·NCT06556108·5 enrolled

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors

Recruiting·GGuangzhou FineImmune Biotechnology Co., LTD.·Phase 1·NCT06302062·23 enrolled

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Terminated·AAdaptimmune·Phase 1·NCT04526509·12 enrolled

Melanoma4 trials

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Withdrawn·JJames Isaacs, MD·Phase 1·NCT06190249

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

Completed·SSt. Luke's Medical Center·Phase 2·NCT00002535

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01585415·12 enrolled

Show 1 more trial

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Completed·CCraig L Slingluff, Jr·Phase 1/2·NCT00118274·170 enrolled

Non-Small Cell Lung Cancer3 trials

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02133196·85 enrolled

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Withdrawn·IImmunityBio, Inc.·Phase 2·NCT03574649

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Completed·EECOG-ACRIN Cancer Research Group·Phase 2·NCT00828009·70 enrolled

Metastatic Cancer3 trials

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01583686·15 enrolled

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00704938·3 enrolled

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01273181·9 enrolled

Hematologic Cancer2 trials

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00723099·73 enrolled

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

Terminated·UUniversity of Rochester·N/A·NCT00255684·16 enrolled

Multiple Sclerosis2 trials

Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00014755·35 enrolled

High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis

Completed·—·Phase 2·NCT00040482·10 enrolled

Lupus Nephritis2 trials

Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis

Completed·ZZhi-Hong Liu, M.D.·N/A·NCT00876616·362 enrolled

The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis

Terminated·—·Phase 3·NCT01015456·59 enrolled

Medulloblastoma2 trials

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Completed·GGiselle Sholler·Phase 2·NCT00601003·112 enrolled

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01878617·660 enrolled

Primary Systemic Amyloidosis2 trials

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Completed·SSWOG Cancer Research Network·Phase 2·NCT00064337·104 enrolled

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed

Completed·PPETHEMA Foundation·Phase 2·NCT01194791·30 enrolled

Ovarian Cancer2 trials

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Completed·UUniversity of Chicago·Phase 1/2·NCT00003136·11 enrolled

OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)

Withdrawn·IImmetacyte Ltd·Phase 1/2·NCT04389229

Germ Cell Tumor2 trials

Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor

Unknown status·SSamsung Medical Center·Phase 2·NCT02784054·25 enrolled

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00002594·31 enrolled

Immunotherapy1 trial

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT01145209·32 enrolled

Ovarian Epithelial Cancer1 trial

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

Terminated·GGynecologic Oncology Group·Phase 3·NCT00002819

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Graft Versus Host Disease1 trial

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00691015·48 enrolled

Relapsed or Refractory B-cell Hematologic Malignancies1 trial

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recruiting·MMayo Clinic·Phase 1·NCT06191887·27 enrolled

Ewing's Sarcoma1 trial

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00061893·38 enrolled

Stage IV Ovarian Epithelial Cancer1 trial

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery

Completed·EEBMT Solid Tumors Working Party·Phase 3·NCT00004921

AIN1 trial

Autologous Transplant Targeted Against Crohn's

Withdrawn·NNorthwestern University·Phase 2·NCT04154735

Hematologic Malignancies1 trial

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Withdrawn·BBaptist Health South Florida·Phase 2·NCT04282174

Glioblastoma Multiforme1 trial

Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme

Unknown status·—·Phase 1·NCT02844062·20 enrolled

PrEP1 trial

Intensified Rituimab Prephase Before FCR in Untreated B-CLL

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT01370772·140 enrolled

Kidney Cancer1 trial

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

Completed·CChildren's Oncology Group·Phase 3·NCT00002611·3,031 enrolled

Decitabine-primed Tandem CD19/CD20 CAR T Cells1 trial

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Active, not recruiting·HHan weidong·Phase 1/2·NCT04697940·33 enrolled

Pembrolizumab1 trial

Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)

Completed·GGenexine, Inc.·Phase 1/2·NCT03752723·84 enrolled

Peripheral Blood Stem Cell Transplantation1 trial

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Recruiting·HHannah Choe, MD·Phase 2·NCT07249346·124 enrolled

Richter's Transformation1 trial

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Recruiting·—·Phase 2·NCT05672173·20 enrolled

Squamous Cell Carcinoma1 trial

IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

Completed·BBrooklyn ImmunoTherapeutics, LLC·Phase 2·NCT02609386·105 enrolled

Recurrent or Refractory1 trial

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Active, not recruiting·SStanford University·Phase 1·NCT03233854·56 enrolled

Treatment1 trial

LAL-BR/2001: Study Treatment to Low Risk ALL

Completed·PPETHEMA Foundation·Phase 4·NCT00526175·150 enrolled

Acute Myeloid Leukemia1 trial

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·WWashington University School of Medicine·Phase 1·NCT02057770·25 enrolled

Renal Cell Carcinoma1 trial

Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

Completed·—·N/A·NCT00073879

Neoadjuvant Chemotherapy1 trial

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Unknown status·JJilin University·Phase 2·NCT02953184·160 enrolled

Prostate Cancer1 trial

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Active, not recruiting·—·Phase 1·NCT05479578·7 enrolled

Thalassemia1 trial

Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

Completed·FFirst Affiliated Hospital of Guangxi Medical University·Phase 4·NCT04009525·823 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00053989·41 enrolled

Granuloma1 trial

Treatment of Wegener's Granulomatosis With Cyclophosphamide

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001155·200 enrolled

Pancreatic Cancer1 trial

A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

Recruiting·SSun Yat-sen University·Phase 1·NCT06898385·9 enrolled

Glioblastoma1 trial

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Terminated·IImmatics Biotechnologies GmbH·Phase 1·NCT01403285·6 enrolled

Fanconi Anemia1 trial

TBI Dose De-escalation for Fanconi Anemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00352976·83 enrolled

Maintenance Therapy1 trial

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT03004287·50 enrolled

Hodgkin's Disease1 trial

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Completed·CChildren's Oncology Group·Phase 3·NCT00005578·219 enrolled

Chemotherapy1 trial

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Recruiting·EEmory University·Phase 2·NCT04469530·55 enrolled

Relapsed/Refractory1 trial

Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07222735·42 enrolled

Malignant Brain Tumors1 trial

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT00238173·2 enrolled

Pediatric ALL1 trial

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT00439296·9 enrolled

Ewing sarcoma1 trial

Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors

Completed·CChildren's Oncology Group·N/A·NCT00618813·35 enrolled

Stem Cell Transplant1 trial

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting·—·Phase 2·NCT00544115·260 enrolled

Transplantation1 trial

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01010217·176 enrolled

Liver Transplant1 trial

Liver Transplantation With Tregs at UCSF

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03654040·42 enrolled

T-cell acute lymphoblastic leukemia1 trial

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02518750·3 enrolled

Clinical Trial1 trial

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Withdrawn·GGC Cell Corporation·Phase 1·NCT06341647

Prophylaxis1 trial

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

Active, not recruiting·MMcMaster University·Phase 2·NCT04202835·80 enrolled

Urothelial Cancer1 trial

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03197571

Hematologic Disorder1 trial

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders

Completed·—·Phase 2·NCT00636909·25 enrolled

Stem Cell Transplantation1 trial

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·NNorthwestern University·Phase 1·NCT00004904

Microscopic Polyangiitis1 trial

Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)

Completed·UUniversity Medical Center Groningen·Phase 3·NCT00103792·84 enrolled

Metastatic Melanoma1 trial

TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)

Completed·—·Phase 1·NCT03475134·18 enrolled

Refractory Hematologic Malignancy1 trial

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

Recruiting·—·Phase 1·NCT06756321·9 enrolled

Triple-Negative Breast Cancer1 trial

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Unknown status·—·Phase 2·NCT05681728·26 enrolled

Myelofibrosis1 trial

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03426969·3 enrolled

Primary Peritoneal Cancer1 trial

Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed·—·Phase 2·NCT00538031·52 enrolled

Acute Leukemia of Ambiguous Lineage1 trial

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled

Dyskeratosis Congenita1 trial

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00455312·36 enrolled

Colorectal Cancer1 trial

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Withdrawn·—·Phase 1·NCT06626256

Lymphoid Malignancies1 trial

Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

Recruiting·NNelson Hamerschlak·Phase 1·NCT05705570·30 enrolled

Osteosarcoma1 trial

Clinical Trial Evaluating Metronomic Chemotherapy in Patients With Metastatic Osteosarcoma

Unknown status·GGrupo de Apoio ao Adolescente e a Crianca com Cancer·Phase 2·NCT03063983·158 enrolled

Intraperitoneal1 trial

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02498912·18 enrolled

Gene Therapy1 trial

Non-Viral TCR Gene Therapy

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04102436

Efficacy1 trial

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

Completed·CCelltrion·Phase 3·NCT02162771·140 enrolled

Hematopoietic Stem Cell Transplantation1 trial

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00668564·18 enrolled

Bone Marrow Transplantation1 trial

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002547·280 enrolled

Fallopian Tube Cancer1 trial

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02948101

Waldenstrom macroglobulinemia1 trial

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

Completed·MMayo Clinic·Phase 2·NCT00711828·21 enrolled

Myeloid Malignancies1 trial

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06383572·44 enrolled

Relapsed or Refractory1 trial

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Recruiting·UUniversity Hospital Heidelberg·Phase 1/2·NCT03676504·68 enrolled

Immunosuppressive Treatment1 trial

Different Immunosuppressive Treatment in iMN

Recruiting·PPeking Union Medical College Hospital·Phase 3·NCT04745728·200 enrolled

Chronic Myelogenous Leukemia1 trial

Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002598·30 enrolled

Unspecified2 trials

Intra-Osseous Co-Transplant of UCB and hMSC

Completed·—·Phase 1·NCT02181478·6 enrolled

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Terminated·—·Phase 1·NCT02774291·3 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

CYTOXAN

NDA NDA012142

Jan 1, 1982

CYTOXAN

NDA NDA012141

Sep 16, 2013

CYCLOPHOSPHAMIDE

NDA NDA203856

Jul 30, 2020

CYCLOPHOSPHAMIDE

NDA NDA212501

Aug 25, 2021

CYCLOPHOSPHAMIDE

NDA NDA210735

Jun 7, 2023

FRINDOVYX

NDA NDA210852

Jun 28, 2023

CYCLOPHOSPHAMIDE

NDA NDA217651

Sep 12, 2023

CYCLOPHOSPHAMIDE

NDA NDA217150

Sources

References

[1]
ClinicalTrials.gov — 3008 trial records for cyclophosphamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Cytoxan drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — cyclophosphamide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for cyclophosphamide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA217150). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Cytoxan. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Baxter Healthcare Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: BBaxter Healthcare Corporation

Patent Landscape[6]

Patent Cliff

Jun 26, 2035

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9662342Jun 26, 2035

10849916Jul 13, 2035

11382923Dec 1, 2035

12329767Feb 15, 2036

10993952Feb 15, 2036